Profile data is unavailable for this security.
About the company
Mesoblast Limited is an Australia-based is developing a range of late-stage product candidates derived from its proprietary mesenchymal lineage cell therapy technology platforms. The Company’s Remestemcel-L is mesenchymal lineage stromal cell product platform and is in late-stage development for treatment of systemic inflammatory diseases, including Pediatric steroid refractory acute Graft versus Host Disease (SR-aGVHD), acute respiratory distress syndrome (ARDS) and Biologic refractory inflammatory bowel disease. Its Rexlemestrocel-L is mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of advanced chronic heart failure (CHF) and chronic low back pain (CLBP) due to degenerative disc disease. Two products are commercialized in Japan and Europe by the Company’s licensees, and it has a commercial partnership in Europe and China for certain Phase III assets.
- Revenue in USD (TTM)7.47m
- Net income in USD-73.06m
- Incorporated2004
- Employees83.00
- LocationMesoblast LtdL 38 55 Collins StMELBOURNE 3000AustraliaAUS
- Phone+61 39639-6036
- Fax+61 39639-6030
- Websitehttps://www.mesoblast.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tango Therapeutics Inc | 36.53m | -101.74m | 837.87m | 140.00 | -- | 3.17 | -- | 22.94 | -1.08 | -1.08 | 0.3865 | 2.48 | 0.0871 | -- | 36.53 | 260,907.10 | -24.25 | -- | -27.59 | -- | -- | -- | -278.54 | -- | -- | -- | 0.00 | -- | 46.93 | -- | 5.95 | -- | -- | -- |
| Nurix Therapeutics Inc | 80.89m | -144.73m | 839.74m | 284.00 | -- | 4.12 | -- | 10.38 | -2.65 | -2.65 | 1.48 | 3.43 | 0.2369 | -- | -- | 284,813.40 | -42.39 | -33.01 | -54.58 | -39.66 | -- | -- | -178.93 | -260.65 | -- | -- | 0.00 | -- | 99.31 | 15.50 | 20.19 | -- | 39.42 | -- |
| National Research Corporation | 148.58m | 30.96m | 850.54m | 435.00 | 28.37 | 17.63 | 23.07 | 5.72 | 1.26 | 1.26 | 6.02 | 2.02 | 1.18 | -- | 11.00 | 341,563.20 | 24.49 | 26.25 | 33.80 | 36.77 | 62.30 | 63.20 | 20.84 | 23.95 | -- | 1,929.64 | 0.4286 | 55.45 | -1.97 | 4.42 | -2.58 | 0.6695 | 21.45 | -5.29 |
| Longboard Pharmaceuticals Inc | 0.00 | -57.95m | 857.11m | 50.00 | -- | 2.73 | -- | -- | -2.25 | -2.25 | 0.00 | 8.07 | 0.00 | -- | -- | 0.00 | -28.45 | -- | -29.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.84 | -- | -- | -- |
| USANA Health Sciences, Inc. | 900.45m | 61.94m | 860.82m | 1.80k | 13.97 | 1.72 | 15.70 | 0.956 | 3.20 | 3.20 | 46.56 | 25.99 | 1.46 | 2.73 | -- | 500,250.00 | 10.03 | 16.23 | 12.49 | 21.75 | 80.98 | 81.42 | 6.88 | 8.96 | 3.20 | -- | 0.0026 | 0.00 | -7.77 | -4.98 | -8.02 | -12.76 | 4.86 | -- |
| Zentalis Pharmaceuticals Inc | 40.56m | -218.90m | 874.17m | 168.00 | -- | -- | -- | 21.55 | -3.36 | -3.36 | 0.5934 | -- | -- | -- | -- | 241,428.60 | -- | -47.40 | -- | -54.18 | -- | -- | -506.16 | -- | -- | -- | -- | -- | -- | -- | -23.39 | -- | 20.76 | -- |
| ALX Oncology Holdings Inc | 0.00 | -160.81m | 886.76m | 72.00 | -- | 4.62 | -- | -- | -3.74 | -3.74 | 0.00 | 3.80 | 0.00 | -- | -- | 0.00 | -58.58 | -34.34 | -66.35 | -36.47 | -- | -- | -- | -7,238.76 | -- | -- | 0.0592 | -- | -- | -- | -30.23 | -- | 14.30 | -- |
| Mesoblast Ltd (ADR) | 7.47m | -73.06m | 888.67m | 83.00 | -- | 0.7934 | -- | 119.03 | -1.44 | -1.44 | 0.1388 | 10.03 | 0.0112 | -- | 3.71 | 89,951.80 | -10.92 | -12.66 | -11.67 | -13.92 | -190.91 | -78.09 | -978.54 | -593.91 | -- | -3.01 | 0.1934 | -- | -26.56 | -15.43 | 10.35 | -- | 5.60 | -- |
| 89bio Inc | 0.00 | -142.19m | 892.26m | 70.00 | -- | 1.63 | -- | -- | -2.01 | -2.01 | 0.00 | 5.75 | 0.00 | -- | -- | 0.00 | -35.86 | -45.50 | -38.49 | -49.31 | -- | -- | -- | -- | -- | -- | 0.0442 | -- | -- | -- | -39.37 | -- | -36.58 | -- |
| Relay Therapeutics Inc | 35.33m | -329.12m | 894.68m | 309.00 | -- | 1.20 | -- | 25.33 | -2.64 | -2.64 | 0.2841 | 5.64 | 0.0376 | -- | -- | 109,371.50 | -35.03 | -28.55 | -37.16 | -29.54 | -- | -- | -931.64 | -998.20 | -- | -- | 0.00 | -- | 1,749.82 | -- | -17.72 | -- | 19.59 | -- |
| Praxis Precision Medicines Inc | 2.45m | -123.28m | 896.45m | 82.00 | -- | 6.61 | -- | 366.35 | -23.64 | -23.64 | 0.3719 | 7.92 | 0.0241 | -- | -- | 29,841.46 | -121.41 | -74.04 | -161.17 | -85.12 | -- | -- | -5,037.88 | -24,589.25 | -- | -- | 0.00 | -- | -- | -- | 42.40 | -- | -4.52 | -- |
| OPKO Health Inc | 863.49m | -188.86m | 906.09m | 3.93k | -- | 0.7236 | -- | 1.05 | -0.2513 | -0.2513 | 1.15 | 1.80 | 0.4133 | 7.80 | 6.89 | 219,718.60 | -9.03 | -7.14 | -10.03 | -8.14 | 36.84 | 34.42 | -21.86 | -13.83 | 1.22 | -15.24 | 0.1574 | -- | -14.01 | -2.70 | 42.49 | -- | -10.19 | -- |
| Arcutis Biotherapeutics Inc | 59.61m | -262.14m | 910.34m | 296.00 | -- | 8.60 | -- | 15.27 | -3.90 | -3.90 | 0.8602 | 0.9161 | 0.1508 | 0.483 | 3.48 | 201,371.60 | -66.31 | -65.64 | -74.24 | -71.72 | 91.63 | -- | -439.79 | -1,513.03 | 6.80 | -8.11 | 0.6947 | -- | 1,517.09 | -- | 15.83 | -- | -- | -- |
| Ocular Therapeutix Inc | 58.44m | -80.74m | 917.53m | 267.00 | -- | 7.48 | -- | 15.70 | -0.9939 | -0.9939 | 0.7233 | 0.7927 | 0.2912 | 2.47 | 2.46 | 218,883.90 | -40.23 | -46.70 | -48.19 | -54.18 | 90.96 | 89.36 | -138.15 | -228.65 | 6.59 | -6.57 | 0.4512 | -- | 13.49 | 96.60 | -13.65 | -- | 26.37 | -- |
| ARS Pharmaceuticals Inc | 30.00k | -54.37m | 917.59m | 24.00 | -- | 3.96 | -- | 30,586.33 | -0.5719 | -0.5719 | 0.0003 | 2.39 | 0.0001 | -- | -- | 1,250.00 | -21.13 | -20.37 | -21.45 | -21.32 | -- | -- | -181,216.70 | -17,491.75 | -- | -- | 0.00 | -- | -97.72 | -- | -56.75 | -- | -17.18 | -- |
| Immunome Inc | 14.02m | -106.81m | 918.93m | 55.00 | -- | 5.53 | -- | 65.55 | -3.33 | -3.33 | 0.7064 | 2.77 | 0.1625 | -- | -- | 254,872.70 | -123.77 | -94.54 | -148.94 | -112.66 | -- | -- | -761.92 | -1,403.15 | -- | -- | 0.00 | -- | -- | -- | -184.68 | -- | 29.52 | -- |
Data as of May 07 2024. Currency figures normalised to Mesoblast Ltd's reporting currency: US Dollar USD
0.59%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 149.12k | 0.13% |
| Penbrook Management LLCas of 31 Mar 2024 | 125.18k | 0.11% |
| Susquehanna Financial Group LLLPas of 31 Dec 2023 | 113.06k | 0.10% |
| Group One Trading LPas of 31 Dec 2023 | 80.71k | 0.07% |
| Chase Investment Counsel Corp.as of 31 Mar 2024 | 59.60k | 0.05% |
| Wells Fargo Advisors Financial Network LLCas of 31 Dec 2023 | 56.08k | 0.05% |
| Lazari Capital Management, Inc.as of 31 Dec 2023 | 47.72k | 0.04% |
| Summit X LLCas of 31 Dec 2023 | 15.51k | 0.01% |
| Rathbones Investment Management Ltd.as of 31 Dec 2023 | 12.22k | 0.01% |
| Tobias Financial Advisors, Inc.as of 31 Mar 2024 | 10.00k | 0.01% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
